News Merck partners Remepy in PDURS-focused alliance Merck KGaA has started working with Remepy on the development of hybrid drugs that combine medicines with digital therapeutics.
News Boehringer transfers schizophrenia DTx selling rights to Cli... Boehringer has altered the terms of its digital therapeutic alliance with Click on schizophrenia app CT-155, taking a more strategic investor role.
News Daiichi teams up with GAIA for cholesterol DTx in Europe Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.
Digital Is DTx finally reaching drug-like efficacy? A Q&A with David... Click Therapeutics CEO David Benshoof Klein shares thoughts on what's been holding DTx back and why this could be the moment for a breakout.
Digital Molecules, DTx, and a breakthrough in chronic cough Early evidence for a cough treatment digital therapeutic is compelling.
Digital Transforming Pharma: Insights from Frontiers Health 2025 pharmaphorum caught up with Emre Ozcan (Merck Group) after his onstage session at Frontiers Health.
News Avalyn seeks $300m from its IPO Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
